Filing Details

Accession Number:
0001209191-17-050586
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-08-29 17:30:04
Reporting Period:
2017-08-28
Accepted Time:
2017-08-29 16:30:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1515673 Ultragenyx Pharmaceutical Inc. RARE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1248093 D Emil Kakkis C/O Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato CA 94949
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-08-28 5,853 $52.40 2,558,094 No 4 P Indirect By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
Common Stock Acquisiton 2017-08-28 1,647 $52.96 2,559,741 No 4 P Indirect By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
No 4 P Indirect By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 430,569 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.89 to $52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.90 to $52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.